AU7007491A - Cdna corresponding to the genome of negative-strand rna viruses, and process for the production of infectious negative-strand rna viruses - Google Patents

Cdna corresponding to the genome of negative-strand rna viruses, and process for the production of infectious negative-strand rna viruses

Info

Publication number
AU7007491A
AU7007491A AU70074/91A AU7007491A AU7007491A AU 7007491 A AU7007491 A AU 7007491A AU 70074/91 A AU70074/91 A AU 70074/91A AU 7007491 A AU7007491 A AU 7007491A AU 7007491 A AU7007491 A AU 7007491A
Authority
AU
Australia
Prior art keywords
negative
rna viruses
strand rna
genome
production
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU70074/91A
Inventor
Not Given Name
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cilag GmbH International
Original Assignee
Schweiz Serum und Impfinstitut Bern
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schweiz Serum und Impfinstitut Bern filed Critical Schweiz Serum und Impfinstitut Bern
Publication of AU7007491A publication Critical patent/AU7007491A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18411—Morbillivirus, e.g. Measles virus, canine distemper
    • C12N2760/18421—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18411—Morbillivirus, e.g. Measles virus, canine distemper
    • C12N2760/18422—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18411—Morbillivirus, e.g. Measles virus, canine distemper
    • C12N2760/18441—Use of virus, viral particle or viral elements as a vector
    • C12N2760/18443—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20211—Vesiculovirus, e.g. vesicular stomatitis Indiana virus
    • C12N2760/20222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AU70074/91A 1990-02-02 1991-01-30 Cdna corresponding to the genome of negative-strand rna viruses, and process for the production of infectious negative-strand rna viruses Abandoned AU7007491A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP90102120 1990-02-02
EP90102120 1990-02-02

Publications (1)

Publication Number Publication Date
AU7007491A true AU7007491A (en) 1991-08-08

Family

ID=8203580

Family Applications (1)

Application Number Title Priority Date Filing Date
AU70074/91A Abandoned AU7007491A (en) 1990-02-02 1991-01-30 Cdna corresponding to the genome of negative-strand rna viruses, and process for the production of infectious negative-strand rna viruses

Country Status (5)

Country Link
EP (1) EP0440219A1 (en)
JP (1) JPH04211377A (en)
AU (1) AU7007491A (en)
CA (1) CA2035386A1 (en)
YU (1) YU17891A (en)

Families Citing this family (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5997859A (en) * 1988-03-21 1999-12-07 Chiron Corporation Method for treating a metastatic carcinoma using a conditionally lethal gene
US6569679B1 (en) 1988-03-21 2003-05-27 Chiron Corporation Producer cell that generates adenoviral vectors encoding a cytokine and a conditionally lethal gene
ATE219519T1 (en) * 1989-01-23 2002-07-15 Chiron Corp RECOMBINANT THERAPIES FOR INFECTIONS AND HYPERPROLIFERATIVE DISORDERS
JP3045581B2 (en) * 1991-10-14 2000-05-29 社団法人北里研究所 Measles vaccine virus strain identification method
ZA937164B (en) * 1992-09-28 1994-05-23 Commw Scient Ind Res Org Delivery system
KR960703172A (en) 1993-11-18 1996-06-19 스티븐 제이. 멘토 Compositions and methods for utilizing conditionally lethal genes
ES2210273T5 (en) * 1994-07-18 2010-03-29 Conzelmann, Karl-Klaus, Prof. Dr. VIRUS WITH NEGATIVE CHAIN NON-SEGMENTED RECOMBINANT INFECTIVE.
US7465574B2 (en) 1994-09-30 2008-12-16 Medimmune, Llc Recombinant RSV virus expression systems and vaccines
US5750396A (en) * 1995-05-08 1998-05-12 St. Judes Children's Research Hospital Stable virus packaging cell lines
DE69510207T3 (en) 1995-08-09 2007-02-15 Schweiz. Serum- & Impfinstitut Bern Process for producing infectious minus-stranded RNA viruses
US6689367B1 (en) 1995-09-27 2004-02-10 The United States Of America As Represented By The Department Of Health And Human Services Production of attenuated chimeric respiratory syncytial virus vaccines from cloned nucleotide sequences
US7846455B2 (en) 1996-07-15 2010-12-07 The United States Of America As Represented By The Department Of Health And Human Services Attenuated chimeric respiratory syncytial virus
US7485440B2 (en) 1995-09-27 2009-02-03 The United States Of America As Represented By The Department Of Health And Human Services Production of attenuated respiratory syncytial virus vaccines involving modification of M2 ORF2
EP0864645B9 (en) 1995-10-31 2006-03-22 Dnavec Research Inc. Negative-strand rna virus vector having autonomously replicating activity
JP3992200B2 (en) * 1995-11-01 2007-10-17 株式会社ディナベック研究所 Membrane fusible liposome using recombinant Sendai virus
CA2236378C (en) 1995-11-01 2011-01-25 Dnavec Research Inc. Recombinant sendai virus
US6699476B1 (en) 1996-07-15 2004-03-02 Peter L. Collins Production of recombinant respiratory syncytial viruses expressing immune modulatory molecules
BRPI9710363B8 (en) * 1996-07-15 2021-07-06 Us Gov Health & Human Serv attenuated recombinant respiratory syncytial virus (rsv) particle, vaccine to induce protection against recombinant respiratory syncytial virus (rsv), expression vector, and method of producing an infectious recombinant respiratory syncytial virus (rsv).
JP2001500738A (en) 1996-09-17 2001-01-23 カイロン コーポレイション Compositions and methods for treating intracellular diseases
AU4427897A (en) * 1996-09-27 1998-04-17 American Cyanamid Company 3' genomic promoter region and polymerase gene mutations responsible for att enuation in viruses of the order designated mononegavirales
EP0839912A1 (en) * 1996-10-30 1998-05-06 Instituut Voor Dierhouderij En Diergezondheid (Id-Dlo) Infectious clones of RNA viruses and vaccines and diagnostic assays derived thereof
US6544523B1 (en) 1996-11-13 2003-04-08 Chiron Corporation Mutant forms of Fas ligand and uses thereof
US7208161B1 (en) 1997-05-23 2007-04-24 The United States Of America, Represented By The Secretary, Department Of Health And Human Services Production of attenuated parainfluenza virus vaccines from cloned nucleotide sequences
US7951383B2 (en) 1997-05-23 2011-05-31 The United States Of America As Represented By The Department Of Health And Human Services Attenuated parainfluenza virus (PIV) vaccines
US6410023B1 (en) 1997-05-23 2002-06-25 United States Of America Recombinant parainfluenza virus vaccines attenuated by deletion or ablation of a non-essential gene
US7314631B1 (en) 1997-05-23 2008-01-01 The United States Of America As Represented By The Department Of Health And Human Services Use of recombinant live-attenuated parainfluenza virus (PIV) as a vector to protect against disease caused by PIV and respiratory syncytial virus (RSV)
US20030082209A1 (en) 2000-07-05 2003-05-01 Skiadopoulos Mario H. Attenuated human-bovine chimeric parainfluenza virus (PIV) vaccines
US7250171B1 (en) 1997-05-23 2007-07-31 United States Of America As Represented By The Dept. Of Health & Human Services Construction and use of recombinant parainfluenza viruses expressing a chimeric glycoprotein
KR100702523B1 (en) * 1997-05-23 2007-04-04 더 가번먼트 오브 더 유나이티드 스테이츠 오브 아메리카, 에즈 레프리젠티드 바이 더 디파트먼트 오브 헬쓰 앤드 휴먼 서비시즈 Production of attenuated parainfluenza virus vaccines from cloned nucleotide sequences
US7201907B1 (en) 1997-05-23 2007-04-10 The United States Of America, Represented By The Secretary, Department Of Health And Human Services Attenuated human-bovine chimeric parainfluenza virus(PIV) vaccines
US7632508B2 (en) 1997-05-23 2009-12-15 The United States Of America Attenuated human-bovine chimeric parainfluenza virus (PIV) vaccines
DE69838584T2 (en) 1997-08-04 2008-06-26 Cell Genesys, Inc., Foster City ENHANCERS OF HUMAN GLANDULAR CALLIQUE, VECTORS CONTAINING HIM, AND METHODS FOR ITS USE
US6830748B1 (en) 1997-09-26 2004-12-14 Medimmune Vaccines, Inc. Recombinant RSV virus expression systems and vaccines
ATE476508T1 (en) 1997-11-06 2010-08-15 Novartis Vaccines & Diagnostic NEISSERIAL ANTIGENS
EP2210945B1 (en) 1998-01-14 2013-06-26 Novartis Vaccines and Diagnostics S.r.l. Neisseria meningitidis antigens
NZ508366A (en) 1998-05-01 2004-03-26 Chiron Corp Neisseria meningitidis antigens and compositions
EP1953229A3 (en) 1998-10-15 2008-12-24 Novartis Vaccines and Diagnostics, Inc. Metastatic breast and colon cancer regulated genes
ATE519840T1 (en) 1998-12-16 2011-08-15 Novartis Vaccines & Diagnostic HUMAN CYCLIN DEPENDENT KINASE (HPNQALRE)
EP1157121B1 (en) 1999-03-08 2013-04-24 Boehringer Ingelheim Vetmedica GmbH Prrsv replicon
US6864235B1 (en) 1999-04-01 2005-03-08 Eva A. Turley Compositions and methods for treating cellular response to injury and other proliferating cell disorders regulated by hyaladherin and hyaluronans
AU4482200A (en) 1999-04-22 2000-11-10 United States Department Of Agriculture Porcine reproductive and respiratory syndrome vaccine, based on isolate ja-142
US7368261B1 (en) 1999-04-30 2008-05-06 Novartis Vaccines And Diagnostics Srl Conserved Neisserial antigens
GB9911683D0 (en) 1999-05-19 1999-07-21 Chiron Spa Antigenic peptides
WO2001004335A2 (en) 1999-07-09 2001-01-18 The Government Of The United States Of America, As Represented By The Department Of Health And Humanservices Human-bovine chimeric respiratory syncytial virus vaccines
GB9916529D0 (en) 1999-07-14 1999-09-15 Chiron Spa Antigenic peptides
CN1384877B (en) * 1999-08-02 2010-10-27 惠氏 Rescue of mumps virus from cDNA
MXPA02004283A (en) 1999-10-29 2002-10-17 Chiron Spa Neisserial antigenic peptides.
DK1248647T3 (en) 2000-01-17 2010-09-27 Novartis Vaccines & Diagnostic Outer membrane vesicle (OMV) vaccine comprising N. meningitidis serogroup B outer membrane proteins
EP1950297A2 (en) 2000-05-31 2008-07-30 Novartis Vaccines and Diagnostics, Inc. Compositions and methods for treating neoplastic disease using chemotherapy and radiation sensitizers
US7691821B2 (en) 2001-09-19 2010-04-06 University Of South Florida Inhibition of SHIP to enhance stem cell harvest and transplantation
US20020165192A1 (en) 2000-09-19 2002-11-07 Kerr William G. Control of NK cell function and survival by modulation of ship activity
MXPA03003690A (en) 2000-10-27 2004-05-05 Chiron Spa Nucleic acids and proteins from streptococcus groups a b.
WO2002098457A2 (en) * 2001-01-17 2002-12-12 Thomas Jefferson University Recombinant rhabdoviruses as live-viral vaccines for immunodeficiency viruses
GB0107661D0 (en) 2001-03-27 2001-05-16 Chiron Spa Staphylococcus aureus
GB0107658D0 (en) 2001-03-27 2001-05-16 Chiron Spa Streptococcus pneumoniae
NZ562929A (en) 2001-12-12 2009-07-31 Novartis Vaccines & Diagnostic Immunisation against chlamydia trachomatis
DE60233038D1 (en) 2002-06-20 2009-09-03 Pasteur Institut Infectious cDNA of an approved measles virus vaccine strain. Use in immunogenic compositions
ES2427139T3 (en) 2002-06-20 2013-10-29 Institut Pasteur Recombinant measles viruses expressing epitopes of RNA virus antigens and use of recombinant viruses for the preparation of vaccine compositions
US20070059329A1 (en) 2002-11-15 2007-03-15 Nathalie Norais Unexpected surface proteins in meningococcus
CA2432738A1 (en) * 2003-02-26 2004-08-26 Philippe Despres New dengue and west nile viruses proteins and genes coding the foregoing, and their use in vaccinal, therapeutic and diagnostic applications
GB0308198D0 (en) 2003-04-09 2003-05-14 Chiron Srl ADP-ribosylating bacterial toxin
US7807646B1 (en) 2003-11-20 2010-10-05 University Of South Florida SHIP-deficiency to increase megakaryocyte progenitor production
US7763592B1 (en) 2003-11-20 2010-07-27 University Of South Florida SHIP-deficiency to increase megakaryocyte progenitor production
US8268324B2 (en) 2004-03-29 2012-09-18 Galpharma Co., Ltd. Modified galectin 9 proteins and use thereof
TW200604526A (en) 2004-06-18 2006-02-01 Unviersity Of Minnesota Identifying virally infected and vaccinated organisms
US7632636B2 (en) 2004-09-21 2009-12-15 Boehringer Ingelheim Vetmedica, Inc. Porcine reproductive and respiratory syndrome isolates and methods of use
PT1904631E (en) 2005-06-24 2012-07-16 Univ Minnesota Prrs viruses, infectious clones, mutants thereof, and methods of use
EP2054431B1 (en) 2006-06-09 2011-08-31 Novartis AG Conformers of bacterial adhesins
US8673859B2 (en) 2007-03-20 2014-03-18 New York University GM-CSF cosmeceutical compositions and methods of use thereof
TWI627281B (en) 2009-09-02 2018-06-21 百靈佳殷格翰家畜藥品公司 Methods of reducing viricidal activity in pcv-2 compositions and pcv-2 compositions with an improved immunogenicity
MX346636B (en) 2011-02-17 2017-03-27 Boehringer Ingelheim Vetmedica Gmbh Commercial scale process for production of prrsv.
DK2675475T3 (en) 2011-02-17 2015-09-14 Boehringer Ingelheim Vetmed NEW EUROPEAN PRRSV TRIAL
US9187731B2 (en) 2011-07-29 2015-11-17 Boehringer Ingelheim Vetmedica Gmbh PRRS virus inducing type I interferon in susceptible cells
WO2013017570A1 (en) 2011-07-29 2013-02-07 Boehringer Ingelheim Vetmedica Gmbh Novel prrs virus inducing type i interferon in susceptible cells
CN105073130A (en) 2013-03-15 2015-11-18 勃林格殷格翰动物保健公司 Porcine reproductive and respiratory syndrome virus, compositions, vaccine and methods of use
CA2953917C (en) 2013-07-01 2021-10-19 The Research Foundation For The State University Of New York Ship inhibition to combat obesity
WO2015195812A1 (en) 2014-06-17 2015-12-23 The Research Foundation For The State University Of New York Ship inhibition to induce activation of natural killer cells

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0237686A1 (en) * 1986-03-18 1987-09-23 Institut Pasteur DNA sequences derived from the rabies virus genome

Also Published As

Publication number Publication date
JPH04211377A (en) 1992-08-03
YU17891A (en) 1994-09-09
CA2035386A1 (en) 1991-08-03
EP0440219A1 (en) 1991-08-07

Similar Documents

Publication Publication Date Title
AU7007491A (en) Cdna corresponding to the genome of negative-strand rna viruses, and process for the production of infectious negative-strand rna viruses
CA2154023A1 (en) Recombinant infectious non-segmented negative strand rna virus
HU914073D0 (en) New 5-chloro-quinoline-8-oxy-alkane-carboxylic acid derivatives, process for producing them and their utilization as antidote
DE69013313D1 (en) Multi-stage process for the production of hexafluoropropylene.
CA2120942A1 (en) Nitric esters of derivatives of the 2-(2,6-di-halo-phenylamino)phenyl-acetic acid and process for their preparation
NO305158B1 (en) Process for preparing catalysts for use in the production of vinyl acetate
DE69008326T2 (en) Multi-stage process for the production of hexafluoropropylene.
AU6518890A (en) 6-amino-1,2-benzopyrones useful for treatment of viral diseases
LTIP863A (en) Aminobenzodiazepines, process for preparing thereof and application for the treatment and prevention of viral diseases
FI98067C (en) Novel alkylenediammonium diclavulanate derivatives, process for their preparation as well as their use for the purification of calvulanic acid
DE69332376D1 (en) RARELY CONNECTED MAGNET, COMPOSITION THEREFOR AND PRODUCTION PROCESS
DE69010171D1 (en) Multi-stage process for the production of hexafluoropropylene.
HU913398D0 (en) Process for the production of new muramyl-dipeptide derivatives and influenza vaccines containing them
DE69330238T2 (en) Process for the production of the hepatitis C virus ectoprotein
AU1226288A (en) Processes for the preparation of medicinal compositions, compositions obtained by these processes and use thereof for the preparation of medicines against viral hepatitis b and acquired immunodeficiency syndrome
AU9128391A (en) Bovine respiratory syncytial virus genes
ZA898101B (en) Bromonitro compound,process for the production thereof and use as blocide
DE69413946D1 (en) Process for the production of high-purity 2,6-naphthalenedicarboxylic acid
AU8252387A (en) New furanuronic acid derivatives, process for their production and their use
AU8306987A (en) Novel carbamoyloxylabdanes, intermediates and a process for the preparation thereof and their use as medicaments
ATE209683T1 (en) PLANT RESISTANT TO AT LEAST TWO VIRUSES AND ITS PREPARATION
KR960701075A (en) New 2'-methylidene nucleotide compound, preparation method thereof, and pharmaceutical use thereof [NOVEL 2'-METHYLIDENENUCLEOTIDE COMPOUND, PROCESS FOR PRODUCING THE SAME, AND PHARMACEUTICAL USE THEREOF]
HU913228D0 (en) Process for the production of 5-aroil-2,3-dihydro-1h-pyrrholyzine-1,1-dicarboxylates
GB9516444D0 (en) Process for the production of n,n-dimethyl-n'-phenylureas
AU8207191A (en) A group of bacteria belonging to the order of actionomycetales, a biocidal compound producible thereof and a process for producing the compound